Publications by authors named "Frances Visco"
Background: Ribociclib has been shown to have a significant overall survival benefit in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. Whether this benefit in advanced breast cancer extends to early breast cancer is unclear.
Methods: In this international, open-label, randomized, phase 3 trial, we randomly assigned patients with HR-positive, HER2-negative early breast cancer in a 1:1 ratio to receive ribociclib (at a dose of 400 mg per day for 3 weeks, followed by 1 week off, for 3 years) plus a nonsteroidal aromatase inhibitor (NSAI; letrozole at a dose of 2.
Article Synopsis
- Ribociclib has been shown to improve overall survival for patients with HR+/HER2- advanced breast cancer, and the NATALEE trial aims to evaluate its safety and effectiveness when combined with endocrine therapy for early nonmetastatic cases.* -
- This Phase III trial involves a randomized, multicenter design, enrolling men and women with specific stages of breast cancer, and compares ribociclib with endocrine therapy alone, focusing on invasive disease-free survival as the main outcome.* -
- The trial extends ribociclib treatment to 36 months to enhance effectiveness and uses a lower dosage to improve tolerability, including a diverse patient population for more comprehensive results on adjuvant therapy.*
Background: Trastuzumab improves survival in the adjuvant treatment of HER-positive breast cancer, although combined therapy with anthracycline-based regimens has been associated with cardiac toxicity. We wanted to evaluate the efficacy and safety of a new nonanthracycline regimen with trastuzumab.
Methods: We randomly assigned 3222 women with HER2-positive early-stage breast cancer to receive doxorubicin and cyclophosphamide followed by docetaxel every 3 weeks (AC-T), the same regimen plus 52 weeks of trastuzumab (AC-T plus trastuzumab), or docetaxel and carboplatin plus 52 weeks of trastuzumab (TCH).
Each year, over 200,000 people are diagnosed with breast cancer in the United States. Although the use of biomarkers has the potential to guide preventive interventions and improve survival and quality of life, there have been few successes and many disappointments. In November 2005, the National Breast Cancer Coalition Fund convened a conference aimed at developing a patient-centred, strategic approach to breast cancer biomarker research.
View Article and Find Full Text PDFObjective: To evaluate the impact of having breast cancer survivors with advocacy experience (consumers) participate as voting members of scientific review panels for proposals on breast cancer research. As major stakeholders, patients and other consumer advocates sought inclusion in all decision-making processes affecting funding of disease-targeted research.
Method: Cross-sectional analysis of assigned proposal scores ranging from 5.